Nov 06, 2023 / 02:50PM GMT
Vamil Divan - Guggenheim Securities LLC - Analyst
Okay then, we're going to get started here. Thanks, everyone, for joining us. The next discussion here, we have Vera Therapeutics. I'm Vamil Divan, by the way, from the Guggenheim side, one of the analysts here. Joined with me up here we have Marshall Fordyce, who's the CEO and Founder of Vera; and as well as Sean Grant, the CFO.
So great, thanks so much for joining us for the conference. First of all, I think it's a great time to have you here. We're coming right off of a pretty exciting ASN meeting where IgAN certainly had a lot of focus.
So maybe, Marshall, just on kicking things off, maybe a couple of minutes just on the background of the company or sort of the developed -- the progress you guys have made. And then maybe, is there any key thoughts you have coming out of ASN? And I'm sure we have a lot to follow up on, but maybe I'll just start there?
Marshall Fordyce - Vera Therapeutics, Inc. - CEO & Founder
Definitely. Thanks so much, Vamil, for the opportunity here. It's great to be
Vera Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 06, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers